Annie Mcguire Sells 1,422 Shares of Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. (NASDAQ:VCYT) SVP Annie Mcguire sold 1,422 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $47.30, for a total transaction of $67,260.60. Following the completion of the sale, the senior vice president owned 78,499 shares of the company’s stock, valued at $3,713,002.70. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Annie Mcguire also recently made the following trade(s):

• On Wednesday, November 5th, Annie Mcguire sold 6,466 shares of Veracyte stock. The shares were sold at an average price of $40.00, for a total transaction of $258,640.00.
• On Friday, September 19th, Annie Mcguire sold 2,283 shares of Veracyte stock. The shares were sold at an average price of $33.69, for a total value of $76,914.27.

Veracyte Price Performance

NASDAQ VCYT traded down $0.34 on Thursday, hitting $47.41. The stock had a trading volume of 895,484 shares, compared to its average volume of 974,443. The business’s fifty day moving average price is $39.11 and its 200 day moving average price is $31.88. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of 124.77 and a beta of 1.83. Veracyte, Inc. has a 52-week low of $22.61 and a 52-week high of $50.71.

Veracyte (NASDAQ:VCYT) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.19. Veracyte had a return on equity of 7.23% and a net margin of 6.12%.The company had revenue of $131.87 million for the quarter, compared to analyst estimates of $124.62 million. During the same period in the prior year, the company posted $0.33 EPS. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Veracyte, Inc. will post 0.68 EPS for the current year.

Wall Street Analysts Forecast Growth

VCYT has been the subject of several analyst reports. Canaccord Genuity Group increased their price objective on Veracyte from $40.00 to $43.00 and gave the stock a “hold” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded Veracyte from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. UBS Group lifted their price objective on Veracyte from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Guggenheim increased their target price on shares of Veracyte from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Veracyte in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.38.

Institutional Investors Weigh In On Veracyte

Several large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Veracyte by 12.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,368 shares of the biotechnology company’s stock valued at $871,000 after acquiring an additional 3,201 shares in the last quarter. Blair William & Co. IL raised its stake in shares of Veracyte by 3.5% in the 1st quarter. Blair William & Co. IL now owns 16,092 shares of the biotechnology company’s stock valued at $477,000 after purchasing an additional 550 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Veracyte by 0.6% during the first quarter. Vanguard Group Inc. now owns 8,263,643 shares of the biotechnology company’s stock worth $245,017,000 after purchasing an additional 52,031 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Veracyte by 2.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 740,631 shares of the biotechnology company’s stock worth $21,960,000 after purchasing an additional 19,662 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in Veracyte during the first quarter worth $48,000.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.